Patents by Inventor Keisuke Narukawa

Keisuke Narukawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
    Patent number: 9127280
    Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: September 8, 2015
    Assignees: Osaka University, National Cerebral and Cardiovascular Center, Tokyo University of Science Education Foundation Administrative Organization
    Inventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki
  • OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT
    Publication number: 20130172402
    Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
    Type: Application
    Filed: August 31, 2011
    Publication date: July 4, 2013
    Applicants: Osaka University, Tokyo University of Science Educational Foundation Administrative Organization, National Cerebral and Cardiovascular Center
    Inventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki